These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 28899222)

  • 1. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
    Garg SK; Henry RR; Banks P; Buse JB; Davies MJ; Fulcher GR; Pozzilli P; Gesty-Palmer D; Lapuerta P; Simó R; Danne T; McGuire DK; Kushner JA; Peters A; Strumph P
    N Engl J Med; 2017 Dec; 377(24):2337-2348. PubMed ID: 28899222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HbA
    Danne T; Cariou B; Banks P; Brandle M; Brath H; Franek E; Kushner JA; Lapuerta P; McGuire DK; Peters AL; Sawhney S; Strumph P
    Diabetes Care; 2018 Sep; 41(9):1981-1990. PubMed ID: 29937431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
    Buse JB; Garg SK; Rosenstock J; Bailey TS; Banks P; Bode BW; Danne T; Kushner JA; Lane WS; Lapuerta P; McGuire DK; Peters AL; Reed J; Sawhney S; Strumph P
    Diabetes Care; 2018 Sep; 41(9):1970-1980. PubMed ID: 29937430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
    Bode BW; Cengiz E; Wadwa RP; Banks P; Danne T; Kushner JA; McGuire DK; Peters AL; Strumph P; Sawhney S
    Diabetes Technol Ther; 2021 Jan; 23(1):59-69. PubMed ID: 32640846
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
    Musso G; Gambino R; Cassader M; Paschetta E
    BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
    Baker C; Wason S; Banks P; Sawhney S; Chang A; Danne T; Gesty-Palmer D; Kushner JA; McGuire DK; Mikell F; O'Neill M; Peters AL; Strumph P
    Diabetes Obes Metab; 2019 Nov; 21(11):2440-2449. PubMed ID: 31264767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
    Danne T; Pettus J; Giaccari A; Cariou B; Rodbard H; Weinzimer SA; Bonnemaire M; Sawhney S; Stewart J; Wang S; Castro RC; Garg SK
    Diabetes Technol Ther; 2019 Sep; 21(9):471-477. PubMed ID: 31335194
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes.
    Karges B; Schwandt A; Heidtmann B; Kordonouri O; Binder E; Schierloh U; Boettcher C; Kapellen T; Rosenbauer J; Holl RW
    JAMA; 2017 Oct; 318(14):1358-1366. PubMed ID: 29049584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
    Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
    N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
    Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
    Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
    Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
    Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    Wadwa RP; Reed ZW; Buckingham BA; DeBoer MD; Ekhlaspour L; Forlenza GP; Schoelwer M; Lum J; Kollman C; Beck RW; Breton MD;
    N Engl J Med; 2023 Mar; 388(11):991-1001. PubMed ID: 36920756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
    Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
    Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
    Mathieu C; Dandona P; Gillard P; Senior P; Hasslacher C; Araki E; Lind M; Bain SC; Jabbour S; Arya N; Hansen L; Thorén F; Langkilde AM;
    Diabetes Care; 2018 Sep; 41(9):1938-1946. PubMed ID: 30026335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
    Peters AL; McGuire DK; Danne T; Kushner JA; Rodbard HW; Dhatariya K; Sawhney S; Banks P; Jiang W; Davies MJ; Lapuerta P
    Diabetes Care; 2020 Nov; 43(11):2713-2720. PubMed ID: 32928957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
    Rodbard HW; Giaccari A; Lajara R; Stewart J; Strumph PS; Oliveira J; Lapuerta P; Castro R
    Diabetes Obes Metab; 2020 Nov; 22(11):2089-2096. PubMed ID: 32618383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
    Bhatt DL; Szarek M; Pitt B; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Inzucchi SE; Kosiborod MN; Cherney DZI; Dwyer JP; Scirica BM; Bailey CJ; Díaz R; Ray KK; Udell JA; Lopes RD; Lapuerta P; Steg PG;
    N Engl J Med; 2021 Jan; 384(2):129-139. PubMed ID: 33200891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
    Chatzopoulos G; Tziomalos K
    Expert Opin Pharmacother; 2020 Oct; 21(15):1799-1803. PubMed ID: 33108240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.
    Breton MD; Kanapka LG; Beck RW; Ekhlaspour L; Forlenza GP; Cengiz E; Schoelwer M; Ruedy KJ; Jost E; Carria L; Emory E; Hsu LJ; Oliveri M; Kollman CC; Dokken BB; Weinzimer SA; DeBoer MD; Buckingham BA; Cherñavvsky D; Wadwa RP;
    N Engl J Med; 2020 Aug; 383(9):836-845. PubMed ID: 32846062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
    Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
    N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.